FDA reviewing seven peptides for compounding list, what could this mean for access?
Posted by chemist_daily826 in Research & News - 5 points, 5 comments.
The FDA has an advisory committee meeting on July 23-24 to review seven peptides for possible inclusion on the Section 503A Bulks List, which determines what compounding pharmacies can legally produce. HIMS is apparently pushing a peptides campaign around the same time.
Not gonna lie, I have mixed feelings about this. On one hand, proper oversight on compounded peptides is long overdue. We have all seen how wild the quality can be out there. But the 503A list has historically been used to restrict access as much as to ensure safety, and I worry this meeting leans more toward narrowing things down than opening them up. The article barely touches on which seven peptides are under review, which is frustrating. That detail matters a lot (especially for people who rely on compounded versions of things that are not commercially available).
Does anyone here know which specific peptides are on the agenda for this meeting? I would really like to see the list before speculating too much.
Comments
- runner777: I've been trying to track down the actual agenda for that meeting too and it's a right pain, the FDA briefing documents usually drop a day or two before the committee meets so we might not get specifics until late july which is frustrating when you're trying to plan ahead. I reckon the 503A list has always been a bit of a double-edged thing (good for quality control but historically they've been quite keen to shrink it rather than expand). If anyone finds the specific seven peptides before the m
- chemist_daily826: Yeah the briefing documents timing is what I figured too, but hoping someone here has an inside line or saw a leaked list somewhere. Late July is cutting it close if you are trying to plan around access changes. What are you tracking on your own list, by the way? Curious if there is overlap with what people here commonly use. Might help us narrow down which seven could be on the table.
- fasted_scientist: I feel you, the delay is annoying. I usually check the Federal Register docket a week out, but the peptide names often stay hidden until the briefing drops. If anyone spots the seven before the meeting, posting the docket number would save us all a bit of digging.
- chemist_daily826: Yeah the Federal Register docket idea is good, I should have thought of that myself actually. I was checking the FDA advisory committee page directly and got nothing useful. Did not think about the docket side. If the peptide names stay hidden until the briefing drops though, that is maybe two days before the meeting? Feels like very short notice for people who want to submit public comment. (Though maybe that is the point, not gonna lie.) I will keep an eye on the docket and post the number he
- sleep_coastal: I’ve seen the same thing – the briefing package with the peptide names often shows up just a few days before the meeting, leaving little time for meaningful public comment. I’ll keep an eye on the docket too and post the number if I spot it first.
Community discussion - research and educational context only. Not medical advice.